uniQure (NASDAQ:QURE) Stock Falls 5.5% After Analyst Downgrade

uniQure N.V. (NASDAQ:QURE) dropped 5.5% during trading on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $28.00 price target on the stock, down from their previous price target of $60.00. uniQure traded as low as $21.84 and last traded at $21.5470. 260,059 shares were traded during mid-day trading, a decline of 89% from the average session volume of 2,454,204 shares. The stock had previously closed at $22.80.

QURE has been the subject of a number of other reports. Mizuho upped their price target on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. William Blair upgraded shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. HC Wainwright restated a “buy” rating on shares of uniQure in a research report on Tuesday, September 29th. Finally, Royal Bank Of Canada dropped their price objective on uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.73.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of uniQure during the second quarter worth $15,254. IFP Advisors Inc raised its holdings in shares of uniQure by 39.8% during the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 791 shares during the period. Fulton Bank N.A. bought a new stake in uniQure in the 2nd quarter valued at $220,000. Syon Capital LLC bought a new stake in uniQure in the 2nd quarter valued at $279,000. Finally, Mraz Amerine & Associates Inc. acquired a new position in uniQure in the 2nd quarter worth $390,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

The stock’s 50 day moving average is $42.72 and its two-hundred day moving average is $33.56. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -5.75 and a beta of 1.06. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period in the prior year, the business earned ($0.69) EPS. Analysts expect that uniQure N.V. will post -3.82 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.